ACIP issues recommendations on seasonal influenza vaccines

According to CDC’s 2022–2023 Advisory Committee on Immunization Practices (ACIP) recommendations, all vaccines for the approaching influenza season will be quadrivalent. Trivalent influenza vaccines have been taken out of circulation.

Absent any contraindications, the panel recommends vaccination for all U.S. residents aged 6 months and older, ideally during the months of September and October.

Generally, ACIP does not prefer any one available vaccine over another as long as it is age-appropriate. The exception is the population of people age 65 years and older, who are recommended to receive higher-dose or adjuvanted influenza vaccines—specifically, quadrivalent high-dose inactivated vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (allV4)—if possible. In cases in which these vaccines are not available, older adults can receive another age-appropriate option instead.

The ACIP guidance also offers vaccination recommendations for special populations who have an elevated risk for medical complications if they develop severe influenza, including pregnant people, immunocompromised people, individuals with extremely obesity, and Native populations, among others.